drugset / Trial / NCT04294160
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
Timeline
- Start
- 2020-07-22
- Primary completion
- 2024-09-25
- Completion
- 2024-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BATOPROTAFIB | Small molecule | — | Oral |
| Subject | Dabrafenib | Small molecule | — | Oral |
| Subject | Naporafenib | Small molecule | — | Oral |
| Subject | Rineterkib | Small molecule | — | Oral |
| Subject | Spartalizumab | Monoclonal antibody | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |
| Subject | Trametinib | Small molecule | — | Oral |